We are live on ! Find out more

Kamada

KMDA

Market cap $467M

8.09 USD

-0.22

2.65%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

8.09

0.00

0%

1 day

-2.65%

5 days

-2.18%

1 month

4.25%

3 months

8.45%

6 months

-9.1%

Year to date

15.08%

1 year

18.45%

5 years

50.93%

10 years

71.04%

About: Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

Employees: 462

Healthcare Drug Manufacturers - Specialty & Generic

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 33.3%

Neutral 66.7%

Negative 0%

Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference

REHOVOT, Israel, and HOBOKEN, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that Amir London, Chief Executive Officer, will participate and present at the H.C. Wainwright 28th Annual Global Investment Conference, taking place at the Lotte New York Palace Hotel.

Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders

REHOVOT, Israel and HOBOKEN, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (the “Company”) (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, announced today that it has obtained a tax ruling (the “Ruling”) from the Israel Tax Authority (the “ITA”) with respect to the cash dividend of $0.17 (approximately NIS 0.51) per share on the Company's ordinary shares (totaling approximately $9.8 million) announced on August 17, 2026 (the “Dividend”), expected to be paid on September 17, 2026 (the “Payment Date”), to shareholders of record at the close of business on August 27, 2026 (the “Record Date”).

Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders

AI Exhaustion? 3 Healthcare Stocks With 38% EPS Growth That Could Be The Cure

For investors seeking opportunities outside the AI trade, healthcare stocks can offer diversification without sacrificing exposure to growth. S&P 500 healthcare earnings are projected to rise by 22% YoY in 2027, the second-highest estimated growth rate among the eleven sectors, topped only by technology. According to JPMorgan analysts, at a time when many investors remain highly concentrated in the AI theme, healthcare offers a rare combo of durable growth, tech-like margins, and value.

AI Exhaustion? 3 Healthcare Stocks With 38% EPS Growth That Could Be The Cure

Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026

Dividend to be Paid Consistent with the Company's Cash Dividend Policy Dividend to be Paid Consistent with the Company's Cash Dividend Policy

Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026

Zacks Investment Research

Is Kamada (KMDA) a Solid Growth Stock? 3 Reasons to Think "Yes"

Kamada (KMDA) possesses solid growth attributes, which could help it handily outperform the market.

Is Kamada (KMDA) a Solid Growth Stock? 3 Reasons to Think "Yes"

Zacks Investment Research

KMDA or PRTA: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Kamada (KMDA) and Prothena (PRTA). But which of these two companies is the best option for those looking for undervalued stocks?

KMDA or PRTA: Which Is the Better Value Stock Right Now?

Zacks Investment Research

Wall Street Analysts Think Kamada (KMDA) Could Surge 79.06%: Read This Before Placing a Bet

The consensus price target hints at a 79.1% upside potential for Kamada (KMDA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think Kamada (KMDA) Could Surge 79.06%: Read This Before Placing a Bet

Zacks Investment Research

Should Value Investors Buy Kamada (KMDA) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy Kamada (KMDA) Stock?

Kamada Ltd. (KMDA) Q2 2026 Earnings Call Transcript

Kamada Ltd. (KMDA) Q2 2026 Earnings Call Transcript

Kamada Ltd. (KMDA) Q2 2026 Earnings Call Transcript

Kamada Q2 Earnings Call Highlights

Kamada NASDAQ: KMDA reported record revenue and adjusted EBITDA for the second quarter and first half of 2026, driven by higher sales of its specialty plasma-derived products, including KEDRAB, VARIZIG and HEPAGAM. The company reiterated its full-year guidance and said it expects initial sales under a new plasma supply agreement to begin in the fourth quarter.

Kamada Q2 Earnings Call Highlights

See News Rankings

Price charts implemented using Lightweight Charts™